Cancer Immunotherapy Guidelines

SITC Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints and the sequencing or combination of therapies.

SITC began addressing the deficiency in physician resources on the appropriate use of immunotherapy for melanoma in the 2013 paper, “The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma”. In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces are currently developing consensus statements for genitourinary malignancies, hematologic malignancies and lung cancer. An update of the melanoma consensus statement is also underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.

Melanoma (Cancer Immunotherapy Guidelines-Melanoma)

Melanoma Update (Cancer Immunotherapy Guidelines-MU)

Genitourinary Malignancies (Cancer Immunotherapy Guidelines-GU) – NOW PUBLISHED!

Hematologic Malignancies (Cancer Immunotherapy Guidelines-HEME)

Lung Cancer (Cancer Immunotherapy Guidelines-LC)

Our Experts

SITC follows the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for creating the consensus statement; therefore, each Cancer Immunotherapy Guidelines Task Force comprises a comprehensive mix of scientific researchers, clinical investigators, immunotherapy nursing specialists, patients and patient advocates invited from a diversity of institutions across the United States. Each expert Task Force addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and then develops evidence-based recommendations by recording consensus opinions of the Task Force and documenting alternative opinions when they occur.

Click on a Cancer Immunotherapy Guidelines project above to meet the individuals involved!

Cancer Immunotherapy Guidelines Oversight Committee

In response to the growing need for additional disease-specific Cancer Immunotherapy Guidelines, SITC established a Cancer Immunotherapy Guidelines Oversight Committee to provide a mechanism to strategize all Cancer Immunotherapy Guidelines projects, set standardized Cancer Immunotherapy Guidelines Task Force procedures and ensure a balanced and fair approach to the development and update of all Guidelines projects.

• CHAIR: Madhav Dhodapkar, MD – Yale University
• VICE CHAIR: Ashish Kamat, MD, MBBS, FACS – MD Anderson Cancer Center
• Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
• Michael Bishop, MD – The University of Chicago
• Michael Boyiadzis, MD – University of Pittsburgh
• Julie Brahmer, MD – Johns Hopkins University
• Madhav Dhodapkar, MD – Yale University
• James Gulley, MD, PhD, FACP – National Cancer Institute
• Ramaswamy Govindan, MD – Washington University School of Medicine
• Roy Herbst, MD, PhD – Yale Cancer Center
• F. Stephen Hodi, MD – Dana-Farber Cancer Institute; Co-Chair
• Ashish Kamat, MD, MBBS, FACS – MD Anderson Cancer Center
• Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
• John M. Kirkwood, MD – University of Pittsburgh; Co-Chair
• Douglas G. McNeel, MD, PhD – University of Wisconsin
• Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
• Naiyer Rizvi, MD – Columbia University Medical Center
• Jonathan Rosenberg, MD – Memorial Sloan Kettering Cancer Center